Stockreport

Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation [Seeking Alpha]

Arvinas, Inc.  (ARVN) 
Last arvinas, inc. earnings: 11/4 05:00 pm Check Earnings Report
PDF Arvinas entered into a strategic license agreement with Novartis for the development and commercialization of ARV-766, its second-generation PROTAC androgen receptor de [Read more]